Detalles de la búsqueda
1.
Who is at risk for weight gain after weight-gain associated treatment with antipsychotics, antidepressants, and mood stabilizers: A machine learning approach.
Acta Psychiatr Scand
; 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38561235
2.
Altered amygdalar emotion space in borderline personality disorder normalizes following dialectical behaviour therapy.
J Psychiatry Neurosci
; 48(6): E431-E438, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37935476
3.
Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication.
Eur Arch Psychiatry Clin Neurosci
; 273(4): 839-851, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35778522
4.
Deconstructing depression by machine learning: the POKAL-PSY study.
Eur Arch Psychiatry Clin Neurosci
; 2023 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38091084
5.
A factor analytic comparison of three commonly used depression scales (HAMD, MADRS, BDI) in a large sample of depressed inpatients.
BMC Psychiatry
; 23(1): 548, 2023 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507656
6.
Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders.
Eur Arch Psychiatry Clin Neurosci
; 271(7): 1331-1341, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33733300
7.
Review and Consensus on Pharmacogenomic Testing in Psychiatry.
Pharmacopsychiatry
; 54(1): 5-17, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33147643
8.
Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study.
Eur Arch Psychiatry Clin Neurosci
; 270(5): 597-609, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31302731
9.
Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients.
Eur Arch Psychiatry Clin Neurosci
; 270(4): 425-431, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30523404
10.
The vicious circle of social exclusion and psychopathology: a systematic review of experimental ostracism research in psychiatric disorders.
Eur Arch Psychiatry Clin Neurosci
; 270(5): 521-532, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31586242
11.
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.
Eur Arch Psychiatry Clin Neurosci
; 270(6): 661-671, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31463563
12.
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Pharmacopsychiatry
; 52(4): 180-185, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30235496
13.
[Patients with tic disorders: widely known, yet underserved]. / Patienten mit Tic-Störungen: weit bekannt, doch unterversorgt.
Fortschr Neurol Psychiatr
; 87(10): 577-589, 2019 Oct.
Artículo
en Alemán
| MEDLINE | ID: mdl-31627240
14.
QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.
Eur Arch Psychiatry Clin Neurosci
; 268(4): 383-390, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29429138
15.
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.
Eur Arch Psychiatry Clin Neurosci
; 267(4): 303-313, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27785605
16.
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?
Pharmacopsychiatry
; 50(4): 136-144, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28505669
17.
Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment.
Cogn Neuropsychiatry
; 22(4): 280-297, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28470106
18.
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.
Eur Arch Psychiatry Clin Neurosci
; 265(2): 107-16, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25261210
19.
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors.
Eur Arch Psychiatry Clin Neurosci
; 264(7): 567-75, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24590257
20.
Correction: Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
Pharmacopsychiatry
; 52(4): e1, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32102096